Close this search box.

Stereotactic body radiotherapy in lung metastases from any non haematological primary cancer.

The 90 patients in this trial were randomised into two groups – half received a single high-dose of stereotactic ablative radiotherapy or SABR, and the other had an equivalent dose of SABR but accumulated over four visits. When followed up one year later, there was a little difference in side effects and outcomes. The results indicate that SABR can be a safe and effective treatment for patients whose cancer has spread to their lungs, even when it’s delivered in a single session. In addition to clinical benefits, SABR has practical benefits for patients, such as fewer trips to a clinic, less time off work and lower treatment costs.

Results from this trial have been published in The International Journal of Radiation Oncology, Biology, Physics [Link] and The Journal of Clinical Oncology [Link]

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Lung Cancer Trials Group (ALTG)

Final Accrual


Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

Clinical Trial Registration

Related Post

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing